Who are AMT-676's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): AMG 073, Experimental: SNF472.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/amt-676.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

AMT-676 — Competitive Intelligence Brief

AMT-676 (AMT-676) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Calcimimetic agent. Area: Nephrology / Endocrinology.

phase 2 Calcimimetic agent Calcium-sensing receptor (CaSR) Nephrology / Endocrinology Small molecule Live · refreshed every 30 min

Target snapshot

AMT-676 (AMT-676) — Multitude Therapeutics Inc.. AMT-676 is a small-molecule allosteric modulator of the calcium-sensing receptor (CaSR) that enhances receptor sensitivity to extracellular calcium.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
AMT-676 TARGET	AMT-676	Multitude Therapeutics Inc.	phase 2	Calcimimetic agent	Calcium-sensing receptor (CaSR)
AMG 073	AMG 073	Amgen	marketed	Calcimimetic agent	Calcium-sensing receptor (CaSR)
Experimental: SNF472	Experimental: SNF472	Sanifit Therapeutics S. A.	phase 3	Calcimimetic agent	Calcium-sensing receptor (CaSR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Calcimimetic agent class)

Amgen · 1 drug in this class
Multitude Therapeutics Inc. · 1 drug in this class
Sanifit Therapeutics S. A. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AMT-676 — Competitive Intelligence Brief. https://druglandscape.com/ci/amt-676. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab